Molecular Epidemiology of Telithromycin-Resistant Pneumococci in Finland

Antimicrobial Agents and Chemotherapy
2007.0

Abstract

In our previous study, we described 26 clinical pneumococci with heterogeneous resistance to telithromycin (TEL). In this study, we investigated the molecular epidemiology of these 26 isolates and compared them to erm(B)-positive but TEL-susceptible (Tels) pneumococci (n=66). Published methods were used for antimicrobial susceptibility testing, serotyping, pulsed-field gel electrophoresis (PFGE) typing, and multilocus sequence typing (MLST). PFGE was performed for all TEL-resistant (Telr) isolates, 3 zone isolates, and 22 randomly selected Tels, erm(B)-positive isolates, while MLST and serotyping were only for Telr isolates, with results compared to international databases. Results showed penicillin nonsusceptibility (MIC ≥0.125 g/ml) was less frequent in erm(B)-positive Telr isolates (4/26) than in Tels isolates (50/66) (P<0.0001). The most frequent serotype was 19A. Telr isolates distributed among 7 PFGE types (type A most frequent with 19 isolates), while Tels isolates had more heterogeneous PFGE patterns. MLST types 193, 271, 273 (representatives of global pneumococcal clones) and new STs (2248, 2306, 2307) were found. The presence of multiple PFGE and MLST types suggests TEL resistance capability arose several times in S. pneumoniae. Resistance was likely not caused by TEL selection pressure as all strains were collected in 2002 (before TEL introduction in Finland). All isolates were of clinical origin, capable of causing human diseases (six from invasive infections). We recommend routine TEL susceptibility testing of pneumococci via disk diffusion in a 5%-CO2 atmosphere, especially in areas where erm(B) is a common resistance mechanism.

Knowledge Graph

Similar Paper

Molecular Epidemiology of Telithromycin-Resistant Pneumococci in Finland
Antimicrobial Agents and Chemotherapy 2007.0
High-Level Telithromycin Resistance in a Clinical Isolate of Streptococcus pneumoniae
Antimicrobial Agents and Chemotherapy 2007.0
Telithromycin Resistance in Streptococcus pneumoniae Is Conferred by a Deletion in the Leader Sequence of erm (B) That Increases rRNA Methylation
Antimicrobial Agents and Chemotherapy 2008.0
Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain
Antimicrobial Agents and Chemotherapy 2007.0
Clonal Diversity and Resistance Mechanisms in Tetracycline-Nonsusceptible Streptococcus pneumoniae Isolates in Poland
Antimicrobial Agents and Chemotherapy 2007.0
Polyclonal Population Structure of Streptococcus pneumoniae Isolates in Spain Carrying mef and mef plus erm (B)
Antimicrobial Agents and Chemotherapy 2008.0
Temporal Trends of Antimicrobial Resistance and Clonality of Invasive Streptococcus pneumoniae Isolates in Finland, 2002 to 2006
Antimicrobial Agents and Chemotherapy 2009.0
Mechanisms of Macrolide Resistance among Streptococcus pneumoniae Isolates from Russia
Antimicrobial Agents and Chemotherapy 2008.0
Distribution of Serotypes, Genotypes, and Resistance Determinants among Macrolide-Resistant Streptococcus pneumoniae Isolates
Antimicrobial Agents and Chemotherapy 2010.0
Prevalence, Characteristics, and Molecular Epidemiology of Macrolide and Fluoroquinolone Resistance in Clinical Isolates of Streptococcus pneumoniae at Five Tertiary-Care Hospitals in Korea
Antimicrobial Agents and Chemotherapy 2007.0